Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain

Parikh, Tapan; Bommana, Murali Mohan; Squillante, Emilio

doi:10.1016/j.ejpb.2009.11.001

Cited by 60 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies reported low intensity of a fluorescent probe loaded in unmodified NPs after administration in the brain [25,32] . In most cases (11 out of 14 papers), unmodified PLGA/PLA NPs were found to cross the BBB at a relatively low percentage even after intravenous administration of a high NP dose (5 mg/animal).…”

Section: Unmodified Plga/pla Npsmentioning

confidence: 99%

“…PEG-containing NPs were demonstrated to have advantages such as stabi lity, prolonged blood circulation time, reduced liver distribution and enhanced brain uptake as PEG chains can help adsorb less opsonins and immunoglobulin G, but more apolipoprotein (Apo) E/B [3] . PEGylated NPs PEG-PLGA and PEG-PLA were reported in 10 papers [19,21,25,26,28,32,35,37,39,41] , and were included in the discussion.…”

Section: In Vivo Studiesmentioning

confidence: 99%

“…Among 29 papers cited in this review, 9 papers performed in vitro studies [20,23,24,31,33,37,38,40] , 8 papers focused on in vivo studies [13,15,16,18,21,25,27,30] , and 12 papers did both in vitro and in vivo studies [14,17,19,22,26,28,29,32,34,35,39,41] .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier

Sabliov

2013

Nanotechnology Reviews

View full text Add to dashboard Cite

Abstract:The blood-brain barrier (BBB), which protects the central nervous system (CNS) from unnecessary substances, is a challenging obstacle in the treatment of CNS disease. Many therapeutic agents such as hydrophilic and macromolecular drugs cannot overcome the BBB. One promising solution is the employment of polymeric nanoparticles (NPs) such as poly (lactic-co-glycolic acid) (PLGA) NPs as drug carrier. Over the past few years, significant breakthroughs have been made in developing suitable PLGA and poly (lactic acid) (PLA) NPs for drug delivery across the BBB. Recent advances on PLGA/PLA NPs enhanced neural delivery of drugs are reviewed in this paper. Both in vitro and in vivo studies are included. In these papers, enhanced cellular uptake and therapeutic efficacy of drugs delivered with modified PLGA/PLA NPs compared with free drugs or drugs delivered by unmodified PLGA/ PLA NPs were shown; no significant in vitro cytotoxicity was observed for PLGA/PLA NPs. Surface modification of PLGA/PLA NPs by coating with surfactants/polymers or covalently conjugating the NPs with targeting ligands has been confirmed to enhance drug delivery across the BBB. Most unmodified PLGA NPs showed low brain uptake ( < 1 % ), which indirectly confirms the safety of PLGA/PLA NPs used for other purposes than treating CNS diseases.

show abstract

Section: Unmodified Plga/pla Npsmentioning

confidence: 99%

Section: In Vivo Studiesmentioning

confidence: 99%

See 1 more Smart Citation

PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier

Sabliov

2013

Nanotechnology Reviews

View full text Add to dashboard Cite

show abstract

“…Commendable attempts have been made to evaluate brain targeting using modified nanoparticles (Aktas et al, 2005;Parikh et al, 2010;Kirthivasan et al, 2012), but we believe their methods are found wanting. Most of the current brain-targeting approaches rely on careful studies of the brain tissue post sacrifice of the animals.…”

Section: Three-day In Vivo Brain Microdialysismentioning

confidence: 99%

“…Copolymers (Methoxy-polyethylene glycol-polylactic acid (Met-PEG-PLA) & maleimide-polyethylene glycolpolylactic acid (Mal-PEG-PLA)) were synthesized in the lab according to Parikh et al (2010). Met-PEG-PLA and Mal-PEG-PLA were accurately weighed in the ratio of 8:1.…”

Section: Preparation Of Nanoparticlesmentioning

confidence: 99%